Catalyst Biosciences Statistics Share Statistics Catalyst Biosciences has 13.89M
shares outstanding. The number of shares has increased by 0.09%
in one year.
Shares Outstanding 13.89M Shares Change (YoY) 0.09% Shares Change (QoQ) 0.09% Owned by Institutions (%) 0% Shares Floating 1.26M Failed to Deliver (FTD) Shares 1,940 FTD / Avg. Volume 2.38%
Short Selling Information The latest short interest is 89.17K, so 0% of the outstanding
shares have been sold short.
Short Interest 89.17K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 0.48 and the forward
PE ratio is -3.76.
Catalyst Biosciences's PEG ratio is
0.
PE Ratio 0.48 Forward PE -3.76 PS Ratio 0.13 Forward PS 4.5 PB Ratio -0.88 P/FCF Ratio -2.29 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Catalyst Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.32,
with a Debt / Equity ratio of -0.1.
Current Ratio 3.32 Quick Ratio 2.99 Debt / Equity -0.1 Debt / EBITDA 0.1 Debt / FCF -0.27 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $15.11M Profits Per Employee $4.08M Employee Count 7 Asset Turnover 2.97 Inventory Turnover 0.61
Taxes Income Tax -5.32M Effective Tax Rate -22.91%
Stock Price Statistics The stock price has increased by -74.65% in the
last 52 weeks. The beta is 1.29, so Catalyst Biosciences's
price volatility has been higher than the market average.
Beta 1.29 52-Week Price Change -74.65% 50-Day Moving Average 21.16 200-Day Moving Average 30.43 Relative Strength Index (RSI) 40.79 Average Volume (20 Days) 81,357
Income Statement In the last 12 months, Catalyst Biosciences had revenue of 105.76M
and earned 28.54M
in profits. Earnings per share was 34.
Revenue 105.76M Gross Profit 101.87M Operating Income 16.16M Net Income 28.54M EBITDA 16.16M EBIT n/a Earnings Per Share (EPS) 34
Full Income Statement Balance Sheet The company has 11.81M in cash and 1.6M in
debt, giving a net cash position of 10.21M.
Cash & Cash Equivalents 11.81M Total Debt 1.6M Net Cash 10.21M Retained Earnings -73.45M Total Assets 157.43M Working Capital 137.48M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -3.64M
and capital expenditures -2.31M, giving a free cash flow of -5.96M.
Operating Cash Flow -3.64M Capital Expenditures -2.31M Free Cash Flow -5.96M FCF Per Share -7
Full Cash Flow Statement Margins Gross margin is 96.33%, with operating and profit margins of 15.28% and 26.98%.
Gross Margin 96.33% Operating Margin 15.28% Pretax Margin 21.95% Profit Margin 26.98% EBITDA Margin 15.28% EBIT Margin 15.28% FCF Margin -5.63%
Dividends & Yields CBIO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CBIO is $26,
which is 100.6% higher than the current price. The consensus rating is "Buy".
Price Target $26 Price Target Difference 100.6% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 16, 2025. It was a
backward
split with a ratio of 1:100.
Last Split Date Jun 16, 2025 Split Type backward Split Ratio 1:100
Scores Altman Z-Score 6.85 Piotroski F-Score 6
